Insulet | PODD - Operating Profit


Insulet reported $129.7M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Abbott USD 2.13B 281M Jun/2026
Align Technology USD 191.32M 13.27M Jun/2026
AtriCure USD 9.66M 9.14M Jun/2026
Baxter International USD 276M 210M Jun/2026
Becton, Dickinson and Co. USD 752M 125M Jun/2026
Boston Scientific USD 1.24B 190M Jun/2026
Cardinal Health USD 814M 47M Jun/2026
Cooper Companies USD -31M 243.8M Mar/2026
Dexcom USD 318.3M 63M Jun/2026
Edwards Lifesciences USD 519.5M 4.8M Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Globus Medical USD -45.97M 209.97M Jun/2026
ICU Medical USD 60.43M 30.05M Jun/2026
Inogen USD -7.79M 728K Sep/2024
Insulet USD 129.7M 7.7M Jun/2026
Integra LifeSciences USD 41.29M 29.82M Jun/2026
J&J USD 7.48B 860M Jun/2026
Medtronic USD 2.09B 354M Mar/2026
Merit Medical Systems USD 60.4M 16.25M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Solventum Corp USD 181M 96M Jun/2026
Stryker USD 1.79B 687M Jun/2026
Tandem Diabetes Care USD -13.79M 3.64M Jun/2026
Teleflex USD 73.07M 36.04M Jun/2026
West Pharmaceutical Services USD 179.1M 2M Jun/2026
Zimmer Biomet Holdings USD 344.7M 50.4M Jun/2026